RNA has several theoretical advantages as a therapeutic agent, but exploiting RNA in this fashion has faced several major hurdles. Not only is it unstable and difficult to deliver across hydrophobic cell membranes, but extraneous RNA also activates innate immune nucleic acid sensors, which makes it toxic and inflammatory.
Get full access to this article
View all access options for this article.
References
1.
LiebermanJ.Tapping the RNA world for therapeutics. Nat Struct Mol Biol, 25, 357, 2018.
2.
Titze-de-AlmeidaR., DavidC., and Titze-de-AlmeidaS.S.The race of 10 synthetic RNAi-based drugs to the pharmaceutical market. Pharm Res, 34, 1339, 2017.
3.
KalariyaN., BrassilK., and CalinG.MicroRNAs: clinical trials and potential applications. Clin J Oncol Nurs, 21, 554, 2017.
4.
JamesE.N., Van DorenE., LiC., and KaplanD.L.Silk biomaterials-mediated miRNA functionalized orthopedic devices. Tissue Eng A, 2018 [Epub ahead of print]; DOI: 10.1089/ten.TEA.2017.0455.
5.
Mencía CastañoI., CurtinC.M., DuffyG.P., and O'BrienF.J.Harnessing a novel inhibitory role of miR-16 in osteogenesis by human mesenchymal stem cells for advanced scaffold-based bone tissue engineering. Tissue Eng A, 2018 [Epub ahead of print]; DOI: 10.1089/ten.TEA.2017.0460.
6.
Sezlev BilecenD., UludagH., and HasirciV.Development of PEI-RANK siRNA complex loaded PLGA nanocapsules for the treatment of osteoporosis. Tissue Eng A, 2018 [Epub ahead of print]; DOI: 10.1089/ten.TEA.2017.0476.
7.
JankoM., DietzK., RachorJ., et al.Improvement of bone healing by neutralization of microRNA-335-5p, but not by neutralization of microRNA-92A in bone marrow mononuclear cells transplanted into a large femur defect of the rat. Tissue Eng A, 2018 [Epub ahead of print]; DOI: 10.1089/ten.TEA.2017.0479.
8.
DallasA., TrotsyukA., IlvesH., et al.Acceleration of diabetic wound healing with PHD2- and miR-210-targeting oligonucleotides. Tissue Eng A, 2018 [Epub ahead of print]; DOI: 10.1089/ten.TEA.2017.0484.
9.
KenyonJ.D., SergeevaO., SomozaR.A., et al.Analysis of -5p and -3p strands of miR-145 and miR-140 during mesenchymal stem cell chondrogenic differentiation. Tissue Eng A, 2018 [Epub ahead of print]; DOI: 10.1089/ten.TEA.2017.0440.
10.
PatelS., AthirasalaA., MenezesP.P., et al.Messenger RNA delivery for tissue engineering and regenerative medicine applications. Tissue Eng A, 2018 [Epub ahead of print]; DOI: 10.1089/ten.TEA.2017.0444.
11.
TrepotecZ., AnejaM.K., GeigerJ., HasenpuschG., PlankC., and RudolphC.Maximizing the translational yield of mRNA therapeutics by minimizing 5′-UTRs. Tissue Eng A, 2018 [Epub ahead of print]; DOI: 10.1089/ten.TEA.2017.0485.
12.
ZhangW., De La VegaR.E., CoenenM.J., et al.An improved, chemically modified RNA encoding BMP-2 enhances osteogenesis in vitro and in vivo. Tissue Eng A, 2018 [Epub ahead of print]; DOI: 10.1089/ten.TEA.2018.0112.
13.
HerbstE., ImhoffF.B., FoehrP., et al.Chemically modified messenger RNA: modified RNA application for treatment of achilles tendon defects. Tissue Eng A, 2018 [Epub ahead of print]; DOI: 10.1089/ten.TEA.2017.0443.
14.
SinghR.D., HillestadM.L., LiviaC., et al.M(3) RNA drives targeted gene delivery in acute myocardial infarction. Tissue Eng A, 2018 [Epub ahead of print]; DOI: 10.1089/ten.TEA.2017.0445.
15.
ZaitsevaT.S., AlcazarC., ZamaniM., et al.Aligned nanofibrillar scaffolds for controlled delivery of modified mRNA. Tissue Eng A, 2018 [Epub ahead of print]; DOI: 10.1089/ten.TEA.2017.0494.
